Navigation Links
PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008

MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Conclusions from the in-vitro study show that the LC Sprint Reusable Nebulizer delivered the shortest treatment times, with an average of 4.9 minutes, and had the highest respirable drug delivery rate.

"We found that drug delivery differs between commercially available nebulizers, something for clinicians to consider when contemplating whether patients receive clinically effective doses," said Lisa Cambridge, director of clinical development for PARI Respiratory Equipment, Inc. "Since patient compliance may be associated with the speed of treatment and delivery efficiency, this study highlights key differences between nebulizers."

The study compares the LC Sprint Reusable Nebulizer (PARI Respiratory Equipment), LC PLUS Reusable Nebulizer (PARI Respiratory Equipment), and Sidestream Plus reusable nebulizer (Respironics). Ms. Cambridge presented the results today at CHEST 2008, the annual meeting of the American College of Chest Physicians.

Key conclusions showed:

-- Respirable drug delivery rate (RDDR) was the highest with LC Sprint Reusable Nebulizer -- in fact, RDDR is 46% higher for LC Sprint Reusable Nebulizer compared to Sidestream Plus

-- Respirable dose is similar with LC Sprint and LC PLUS, though RDDR was 25% higher for LC Sprint Reusable Nebulizer

-- Respirable dose and RDDR for LC PLUS Reusable Nebulizer demonstrate higher delivery efficiency (33% and 39% respectively) than Sidestream Plus

-- Treatment times were shortest with LC Sprint Reusable Nebulizer (4.9 minutes)

These conclusions draw upon results from an American Thoracic Society poster (Keller M et al., 2002) that show higher respirable drug delivery rate (RDDR) indicates more drug delivery to the lower airway per minute.

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDI's). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at

Additional information is available by contacting Ayars & Associates at 805-845-5682 or at 804-253-7274 x711.

SOURCE PARI Respiratory Equipment, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ILC Dover Introduces Patient Friendly Respiratory Protection for Health Care Market
2. Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza
3. PARI Respiratory Equipment Featured on Oxygen Network
4. Burning incense increases risk of respiratory tract cancers
5. Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics
6. National Jewish Named the #1 Respiratory Hospital for the Eleventh Year in a Row
7. Temple University Hospital Ranked Among Best in America for Respiratory Disorders by U.S. News & World Report
8. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
9. Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease
10. Respiratory Therapists Offer Breath of Fresh Air During Allergy & Asthma Month
11. New agent strikes at respiratory syncytial virus replication
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology: